The US Food & Drug Administration’s (FDA) Anti-Infective Drugs Advisory Committee has prescribed trail anti-biotic, ceftazidime-avibactam from Actavis plc for treating intricate intra-abdominal diseases (cIAI) and convoluted urinary tract diseases (cUTI) brought on by drug resistant bacteria. The medication has been co developed by Actavis and Astrazeneca plc under an agreement which gives Actavis the […]